Table 5 Association between clinicopathologic factors to TP53 variation and p53 IHC expressions
From: Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
Characteristics | Total | TP53 variation | p | p53 IHC (DO-7) | p | p53 IHC (DO-7) | p | p53 IHC (Bp53–11) | p | p53 IHC (Bp53–11) | p | p53 IHC (SP5) | p | p53 IHC (SP5) | p | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wild | Variation | Wild type pattern (1 ~ 79%) | Aberrant type pattern (0% or ≥ 80%) | Negative (≤55%) | Positive (> 55%) | Wild type pattern (1 ~ 49%) | Aberrant type pattern (0% or > 50%) | Negative (≤50%) | Positive (> 50%) | Wild type pattern (2 ~ 69%) | Aberrant type pattern (≤1% or ≥ 70%) | Negative (≤30%) | Positive (> 30%) | |||||||||
All cases | 204 | 55 (27%) | 149 (73%) | Â | 53 (26%) | 151 (74%) | Â | 80 (39.2%) | 124 (60.8%) | Â | 49 (24%) | 155 (76%) | Â | 88 (43.1%) | 116 (56.9%) | Â | 54 (26.5%) | 150 (73.5%) | Â | 65 (31.9%) | 139 (68.1%) | Â |
Sex | ||||||||||||||||||||||
 Male | 117 | 35 (29.9%) | 82 (70.1%) |  | 34 (29.1%) | 83 (70.9%) |  | 50 (42.7%) | 67 (57.3%) |  | 32 (27.4%) | 85 (72.6%) |  | 53 (45.3%) | 64 (54.7%) |  | 34 (29.1%) | 83 (70.9%) |  | 40 (34.2%) | 77 (65.8%) |  |
 Female | 87 | 20 (23%) | 67 (77%) | 0.27 | 19 (21.8%) | 68 (78.2%) | 0.245 | 30 (34.5%) | 57 (65.5%) | 0.232 | 17 (19.5%) | 70 (80.5%) | 0.197 | 35 (40.2%) | 52 (59.8%) | 0.47 | 20 (23%) | 67 (77%) | 0.331 | 25 (28.7%) | 62 (71.3%) | 0.408 |
Age (years) | ||||||||||||||||||||||
  <  50 | 12 | 4 (33.3%) | 8 (66.7%) |  | 2 (16.7%) | 10 (83.3%) |  | 5 (41.7%) | 7 (58.3%) |  | 3 (25%) | 9 (75%) |  | 5 (41.7%) | 7 (58.3%) |  | 2 (16.7%) | 10 (83.3%) |  | 4 (33.3%) | 8 (66.7%) |  |
  ≥ 50 | 192 | 51 (26.6%) | 141 (73.4%) | 0.608 | 51 (26.6%) | 141 (73.4%) | 0.448 | 75 (39.1%) | 117 (60.9%) | 0.858 | 46 (24%) | 146 (76%) | 0.935 | 83 (43.2%) | 109 (56.8%) | 0.916 | 52 (27.1%) | 140 (72.9%) | 0.427 | 61 (31.8%) | 131 (68.2%) | 0.91 |
Histologic grade | ||||||||||||||||||||||
 Well or Moderate | 167 | 42 (25.1%) | 125 (74.9%) |  | 38 (22.8%) | 129 (77.2%) |  | 64 (38.3%) | 103 (61.7%) |  | 36 (21.6%) | 131 (78.4%) |  | 72 (43.1%) | 95 (56.9%) |  | 42 (25.1%) | 125 (74.9%) |  | 53 (31.7%) | 114 (68.3%) |  |
 Poor | 37 | 13 (35.1%) | 24 (64.9%) | 0.216 | 15 (40.5%) | 22 (59.5%) | 0.026 | 16 (43.2%) | 21 (56.8%) | 0.579 | 13 (35.1%) | 24 (64.9%) | 0.08 | 16 (43.2%) | 21 (56.8%) | 0.989 | 12 (32.4%) | 25 (67.6%) | 0.364 | 12 (32.4%) | 25 (67.6%) | 0.934 |
Site | ||||||||||||||||||||||
 Right side | 69 | 19 (27.5%) | 50 (72.5%) |  | 23 (33.3%) | 46 (66.7%) |  | 34 (49.3%) | 35 (50.7%) |  | 19 (27.5%) | 50 (72.5%) |  | 37 (53.6%) | 32 (46.4%) |  | 21 (30.4%) | 48 (69.6%) |  | 27 (39.1%) | 42 (60.9%) |  |
 Left side | 135 | 36 (26.7%) | 99 (73.3%) | 0.895 | 30 (22.2%) | 105 (77.8%) | 0.087 | 46 (34.1%) | 89 (65.9%) | 0.035 | 30 (22.2%) | 105 (77.8%) | 0.401 | 51 (37.8%) | 84 (62.2%) | 0.031 | 33 (24.4%) | 102 (75.6%) | 0.359 | 38 (28.1%) | 97 (71.9%) | 0.111 |
Tumor size | ||||||||||||||||||||||
  <  4.5 cm | 114 | 24 (21.1%) | 90 (78.9%) |  | 25 (21.9%) | 89 (78.1%) |  | 43 (37.7%) | 71 (62.3%) |  | 25 (21.9%) | 89 (78.1%) |  | 49 (43%) | 65 (57%) |  | 23 (20.2%) | 91 (79.8%) |  | 34 (29.8%) | 80 (70.2%) |  |
  ≥ 4.5 cm | 90 | 31 (34.4%) | 59 (65.6%) | 0.032 | 28 (31.1%) | 62 (68.9%) |  | 37 (41.1%) | 53 (58.9%) | 0.622 | 24 (26.7%) | 66 (73.3%) | 0.432 | 39 (43.3%) | 51 (56.7%) | 0.96 | 31 (34.4%) | 59 (65.6%) | 0.022 | 31 (34.4%) | 59 (65.6%) | 0.482 |
CEA | ||||||||||||||||||||||
  <  5 ng/ml | 158 | 38 (24.1%) | 120 (75.9%) |  | 40 (25.3%) | 118 (74.7%) |  | 64 (40.5%) | 94 (59.5%) |  | 37 (23.4%) | 121 (76.6%) |  | 71 (44.9%) | 87 (55.1%) |  | 38 (24.1%) | 120 (75.9%) |  | 53 (33.5%) | 105 (66.5%) |  |
  ≥ 5 ng/ml | 46 | 17 (37%) | 29 (63%) | 0.083 | 13 (28.3%) | 33 (71.7%) | 0.689 | 16 (34.8%) | 30 (65.2%) | 0.484 | 12 (26.1%) | 34 (73.9%) | 0.709 | 17 (37%) | 29 (63%) | 0.336 | 16 (34.8%) | 30 (65.2%) | 0.147 | 12 (26.1%) | 34 (73.9%) | 0.339 |
T stage | ||||||||||||||||||||||
 T1–3 | 171 | 45 (26.3%) | 126 (73.7%) |  | 43 (25.1%) | 128 (74.9%) |  | 68 (39.8%) | 103 (60.2%) |  | 43 (25.1%) | 128 (74.9%) |  | 75 (43.9%) | 96 (56.1%) |  | 45 (26.3%) | 126 (73.7%) |  | 55 (32.2%) | 116 (67.8%) |  |
 T4 | 33 | 10 (30.3%) | 23 (69.7%) | 0.637 | 10 (30.3%) | 23 (69.7%) | 0.536 | 12 (36.4%) | 21 (63.6%) | 0.714 | 6 (18.2%) | 27 (81.8%) | 0.391 | 13 (39.4%) | 20 (60.6%) | 0.635 | 9 (27.3%) | 24 (72.7%) | 0.909 | 10 (30.3%) | 23 (69.7%) | 0.834 |
N stage | ||||||||||||||||||||||
 N0 | 107 | 36 (33.6%) | 71 (66.4%) |  | 37 (34.6%) | 70 (65.4%) |  | 49 (45.8%) | 58 (54.2%) |  | 34 (31.8%) | 73 (68.2%) |  | 51 (47.7%) | 56 (52.3%) |  | 38 (35.5%) | 69 (64.5%) |  | 37 (34.6%) | 70 (65.4%) |  |
 N1–3 | 97 | 19 (19.6%) | 78 (80.4%) | 0.024 | 16 (16.5%) | 81 (83.5%) | 0.003 | 31 (32%) | 66 (68%) | 0.043 | 15 (15.5%) | 82 (84.5%) | 0.006 | 37 (38.1%) | 60 (61.9%) | 0.17 | 16 (16.5%) | 81 (83.5%) | 0.002 | 28 (28.9%) | 69 (71.1%) | 0.382 |
TNM stage | ||||||||||||||||||||||
 Stage I, II | 110 | 37 (33.6%) | 73 (66.4%) |  | 37 (33.6%) | 73 (66.4%) |  | 51 (46.4%) | 59 (53.6%) |  | 35 (31.8%) | 75 (68.2%) |  | 53 (48.2%) | 57 (51.8%) |  | 37 (33.6%) | 73 (66.4%) |  | 39 (35.5%) | 71 (64.5%) |  |
 Stage III, IV | 94 | 18 (19.1%) | 76 (80.9%) | 0.02 | 16 (17%) | 78 (83%) | 0.007 | 29 (30.9%) | 65 (69.1%) | 0.024 | 14 (14.9%) | 80 (85.1%) | 0.005 | 35 (37.2%) | 59 (62.8%) | 0.116 | 17 (18.1%) | 77 (81.9%) | 0.012 | 26 (27.7%) | 68 (72.3%) | 0.234 |